Picture of Nascent Biotech logo

NBIO Nascent Biotech Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual income statement for Nascent Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

2019
March 31st
2020
March 31st
2021
March 31st
2022
March 31st
2023
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue000.7510
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses1.373.4521.452.13
Operating Profit-1.37-3.45-1.25-0.452-2.13
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-1.37-4-0.959-0.47-2.8
Provision for Income Taxes
Net Income After Taxes-1.37-4-0.959-0.47-2.8
Net Income Before Extraordinary Items
Net Income-1.37-4-0.959-0.47-2.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-1.37-4-0.959-0.47-2.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.045-0.116-0.015-0.004-0.024